Management of malignant gliomas and primary CNS lymphoma: Standard of care and future directions

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 2, 2012, Pages 406-415

  Rosenfeld, Myrna R ^a   Pruitt, Amy A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BEVACIZUMAB; CARMUSTINE; IRINOTECAN; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ADULT; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; COGNITIVE DEFECT; CONFUSION; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DRUG FATALITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; GLIOBLASTOMA; HEADACHE; HEALTH CARE QUALITY; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HUMAN; LYMPHOMA CELL; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TONIC CLONIC SEIZURE; TUMOR GROWTH;

ADULT; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; LYMPHOMA; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; STANDARD OF CARE;

EID: 84859630096     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000413666.88539.0b     Document Type: Review

References (30)

1. CBTRUS. Statistical Report: Primary brain tumors in the United States, 2000-2004. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2008.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109. (Pubitemid 47103521)
3. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. Clin Cancer Res 2010;16(8):2443-2449.
4. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110.
5. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009;100(12):2235-2241.
6. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-1068.
7. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-764.
8. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-1972.
9. Combs SE, Debus J, Schulz-Ertner D. Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 2007;7:167.
10. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996. (Pubitemid 40349501)
11. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-466.
12. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003. (Pubitemid 40349502)
13. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90(19):1473-1479. (Pubitemid 28482012)
14. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66(20):9852-9861. (Pubitemid 44672036)
15. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008-1012.
16. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366(9490):985-990. (Pubitemid 41323034)
17. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20(8):2076-2084. (Pubitemid 34408798)
18. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66(16):7843-7848. (Pubitemid 44299144)
19. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-4740.
20. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-745.
21. Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008;22(2):400-405. (Pubitemid 351250546)
22. Jahnke K, Korfel A, Komm J, et al. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 2006;244(6):663-669. (Pubitemid 43923186)
23. Bellinzona M, Roser F, Ostertag H, et al. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005;31(1):100-105. (Pubitemid 40103933)
24. Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer 2006;106(2):383-387.
25. Schlegel U. Primary CNS lymphoma. Ther Adv Neurol Disord 2009;2(2):93-104.
26. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004;62(3):451-456. (Pubitemid 38200859)
27. Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007;18(7):1145-1151. (Pubitemid 47244358)
28. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-773.
29. Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) 2009;87(4):363-374.
30. Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 2009;15(11):519-530.